1. Search Result
Search Result
Results for "

db/db

" in MedChemExpress (MCE) Product Catalog:

54

Inhibitors & Agonists

11

Peptides

3

Natural
Products

6

Recombinant Proteins

2

Isotope-Labeled Compounds

4

Antibodies

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-137343

    PROTACs Cancer
    DB-0646, a PROTAC, is a multi-kinase degrader .
    <em>DB</em>-0646
  • HY-135797A
    DB1976 dihydrochloride
    4 Publications Verification

    Apoptosis Cancer
    DB1976 dihydrochloride is a selenophene analog of DB270 and a potent and cell-permeable fully efficacious transcription factor PU.1 inhibitor. DB1976 dihydrochloride potently inhibits PU.1 binding (IC50 of 10 nM) and strongly inhibits the PU.1/DNA complex (with high DB1976-λB affinity, KD of 12 nM) in vitro. DB1976 dihydrochloride has apoptosis-inducing effect .
    <em>DB</em>1976 dihydrochloride
  • HY-137345

    Toll-like Receptor (TLR) Cancer
    DB-3-291 is potent and selective CSK degrader, with a Kd of 1 nM .
    <em>DB</em>-3-291
  • HY-135797

    Apoptosis Cancer
    DB1976 is a selenophene analog of DB270 and a potent and cell-permeable fully efficacious transcription factor PU.1 inhibitor. DB1976 potently inhibits PU.1 binding (IC50 of 10 nM) and strongly inhibits the PU.1/DNA complex (with high DB1976-λB affinity, KD of 12 nM) in vitro. DB1976 has apoptosis-inducing effect .
    <em>DB</em>1976
  • HY-114621

    Others Infection
    DB772 hydrate is a bovine viral diarrhoea virus (BVDV) inhibitor. DB772 also has anti-prion activity .
    <em>DB</em>772
  • HY-114621A

    Others Infection
    DB772 hydrate is a bovine viral diarrhoea virus (BVDV) inhibitor. DB772 also has anti-prion activity .
    <em>DB</em>772 hydrate
  • HY-124629

    Apoptosis Cancer
    DB2313 is a potent transcription factor PU.1 inhibitor with an apoptosis of 14 nM. DB2313 disrupts the interaction of PU.1 with target gene promoters. DB2313 induces apoptosis of acute myeloid leukemia (AML) cells, and has anticancer effects .
    <em>DB</em>2313
  • HY-W168754

    Others Others
    DB28 is a novel MR1 ligand. DB28 decreases cell surface expression of MR1 and competitively inhibits activation of MAIT cells by agonist ligands .
    <em>DB</em>28
  • HY-150221

    PARP Cancer
    DB008 is potent and selective PARP16 inhibitor with an IC50 value of 0.27 μM, containing an acrylamide electrophilic reagent. DB008 is membrane-permeable and marks PARP16 selectively . DB008 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    <em>DB</em>008
  • HY-123390

    Bcr-Abl Akt Cancer
    DB07107 is a potent agent resistant T315I mutant Bcr-Abl tyrosine kinase inhibitor. DB07107 is also a potent Akt1 inhibitor with an IC50 value of 360 nM .
    <em>DB</em>07107
  • HY-135237

    Others Neurological Disease Cancer
    DB04760 analog 1 is an analogue of DB04760.
    <em>DB</em>04760 analog 1
  • HY-125166
    DB04760
    1 Publications Verification

    MMP Neurological Disease Cancer
    DB04760 (compound 4) is a potent, highly selective, non-zinc-chelating MMP-13 inhibitor with an IC50 of 8 nM . DB04760 significantly reduces paclitaxel neurotoxicity and has anticancer activity .
    <em>DB</em>04760
  • HY-124676A
    DB2115 tertahydrochloride
    1 Publications Verification

    Apoptosis Cancer
    DB2115 (tertahydrochloride) is a potent inhibitor of myeloid master regulator PU.1. DB2115 (tertahydrochloride) has the potential for researching cancers, including hematologic cancers such as leukemia, as well as other conditions associated with PU. 1 dysfunction (extracted from patent WO2017223260A1, compound DB2115) .
    <em>DB</em>2115 tertahydrochloride
  • HY-131978

    CDK Cancer
    DB18 is a potent and selective inhibitor of CDC2-like kinases (CLKs), with IC50 values in the range of 10-30 nM for CLK1, CLK2 and CLK4. DB18 has anti-tumor activity .
    <em>DB</em>18
  • HY-122623

    Apoptosis Cancer
    DB818 is a potent inhibitor of Homeobox A9 (HOXA9). HOXA9 is a transcription factor regulating haematopoiesis and leukaemia cell proliferation, involving in acute myeloid leukaemia (AML). DB818 inhibits AML cell lines growth, induces apoptosis .
    <em>DB</em>818
  • HY-15737
    DB07268
    4 Publications Verification

    JNK Cancer
    DB07268 is a potent and selective JNK1 inhibitor with an IC50 value of 9 nM.
    <em>DB</em>07268
  • HY-14932A

    db289 maleate

    Parasite Antibiotic Infection
    Pafuramidine (maleate) (DB289 (maleate)) is an orally active proagent of Furamidine (HY-110137A). Pafuramidine (maleate) (DB289 (maleate)) is a potent anti-parasitic agent, can be used to research trypanosomiasis, Pneumocystis pneumonia and malaria .
    Pafuramidine maleate
  • HY-124244

    PPARδ/γ agonist 1

    PPAR Neurological Disease
    DB-959 (PPARδ/γ agonist 1) is a potent dual PPAR delta/gamma inhibitor. DB-959 can be used for Alzheimer’s disease research .
    <em>DB</em>-959
  • HY-148217

    Others Others
    DB02307 is a dipeptide that contains a sequence of two alpha-amino acids joined by a peptide bond .
    <em>DB</em>02307
  • HY-148063

    PROTACs AAK1 Aurora Kinase CaMK CDK Ferroptosis Salt-inducible Kinase (SIK) ULK Wee1 LIM Kinase (LIMK) Others
    DB0614 (Example 21) is a bifunctional compound targeted protein degradation of kinases. DB0614 degrades AAK1, AURKA, BMP2K, CAMKK1, CDK16, CML, CDK6, EIF2AK2, FER, GAK, LCK, LIMK2, MAP3KH, MAPK8, MAPK9, NEK9, PLK4, PTK2B, SIK2, STK17A, STK17B, ULK1, ULK3, and WEE1. DB0614 can be used for research of disease or disorder mediated by aberrant kinase activity .
    <em>DB</em>0614
  • HY-148066

    Others Others
    DB0662 is a compound for kinase-targeted protein degradation and can be used in studies of diseases mediated by abnormal kinase activity, as well as for the identification of degradable kinases and optimal kinases .
    <em>DB</em>0662
  • HY-148061

    PROTACs Bcr-Abl CDK Salt-inducible Kinase (SIK) Cyclin G-associated Kinase (GAK) MAP4K MAPKAPK2 (MK2) Ferroptosis ULK LIM Kinase (LIMK) Others
    DB1113 (Example 24) is a bifunctional compound targeted protein degradation of kinases. DB1113 degrades ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, MAP3K20, MAP4K1, MAP4K2, MAP4K3, MAP4K5, MAPK14, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK3, NLK, PDIK1L, PTK2B, RIPK1, RPS6KA1, RPS6KA3, SIK2, SIK3, STK35, TNK2, and ULK1. DB1113 can be used for research of disease or disorder mediated by aberrant kinase activity .
    <em>DB</em>1113
  • HY-114569A

    Others Cancer
    DH-8P-DB is an anticancer candidate and exhibits cytotoxicity against colon cancer cells .
    DH-8P-<em>DB</em>
  • HY-14932
    Pafuramidine
    1 Publications Verification

    db289

    Parasite Antibiotic Infection
    Pafuramidine (DB289) is an orally active proagent of Furamidine (HY-110137A). Pafuramidine is a potent anti-parasitic agent, can be used to research trypanosomiasis, Pneumocystis pneumonia and malaria .
    Pafuramidine
  • HY-110137A

    db75; NSC 305831

    Histone Methyltransferase Phosphodiesterase (PDE) Parasite Infection Inflammation/Immunology Cancer
    Furamidine (DB75) is a selective protein arginine methyltransferase 1 (PRMT1) inhibitor with an IC50 of 9.4 μM. Furamidine is selective for PRMT1 over PRMT5, PRMT6, and PRMT4 (CARM1) (IC50s of 166 µM, 283 µM, and >400 µM, respectively). Furamidine is a potent, reversible and competitive tyrosyl-DNA phosphodiesterase 1 (TDP-1) inhibitor. Inhibition of TDP-1 by Furamidine is effective both with single- and double-stranded DNA substrates but is slightly stronger with the duplex DNA. Furamidine is also an antiparasite agent .
    Furamidine
  • HY-110137
    Furamidine dihydrochloride
    1 Publications Verification

    db75 dihydrochloride; NSC 305831 dihydrochloride

    Histone Methyltransferase Phosphodiesterase (PDE) Parasite Infection Inflammation/Immunology Cancer
    Furamidine dihydrochloride (DB75 dihydrochloride) is a selective protein arginine methyltransferase 1 (PRMT1) inhibitor with an IC50 of 9.4 μM. Furamidine dihydrochloride is selective for PRMT1 over PRMT5, PRMT6, and PRMT4 (CARM1) (IC50s of 166 µM, 283 µM, and >400 µM, respectively). Furamidine dihydrochloride is a potent, reversible and competitive tyrosyl-DNA phosphodiesterase 1 (TDP-1) inhibitor. Inhibition of TDP-1 by Furamidine dihydrochloride is effective both with single- and double-stranded DNA substrates but is slightly stronger with the duplex DNA. Furamidine dihydrochloride is also an antiparasite agent .
    Furamidine dihydrochloride
  • HY-162042

    AMPK Metabolic Disease
    AMPK activator 14 (compound 32) is an orally active AMPK activator. AMPK activator 14 decreases fasted glucose and insulin levels in a db/db mouse model of Type II diabetes .
    AMPK activator 14
  • HY-P1569

    Arenavirus Inflammation/Immunology
    LCMV gp33-41, the carboxyl-extended 11-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes .
    LCMV gp33-41
  • HY-P1569A

    Arenavirus Inflammation/Immunology
    LCMV gp33-41 (TFA), the carboxyl-extended 11-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes .
    LCMV gp33-41 TFA
  • HY-P5578

    GCGR Metabolic Disease
    A8SGLP-1 is an orally active GLP-1 analogue that the alanine at position 8 substituted with serine. A8SGLP-1 reduces blood glucose in db/db mice without affecting its function .
    A8SGLP-1
  • HY-P5578A

    GCGR Metabolic Disease
    A8SGLP-1 TFA is an orally active GLP-1 analogue that the alanine at position 8 substituted with serine. A8SGLP-1 TFA reduces blood glucose in db/db mice without affecting its function .
    A8SGLP-1 TFA
  • HY-101064

    N-FMOC-leucine; NPC 15199; NSC 334290

    Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity .
    Fmoc-leucine
  • HY-153617

    Others Metabolic Disease
    FOXO1-IN-3 is a highly-selective and orally active FOXO1 inhibitor. FOXO1-IN-3 reduces hepatic glucose production in mice. FOXO1-IN-3 improves insulin sensitivity and glucose control in db/db mice without causing weight gain .
    FOXO1-IN-3
  • HY-128530

    Cuproptosis Others Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Tetrathiomolybdate, an orally active anti-copper agent, reduces copper levels in the body. Tetrathiomolybdate has a protective effect on collagen-induced arthritis in mice. Tetrathiomolybdate also reduces blood sugar, but has no effect on mice with hereditary diabetes (db/db). Tetrathiomolybdate inhibit angiogenesis, also shows antiangiogenic effects in malignant pleural mesothelioma .
    Tetrathiomolybdate
  • HY-131334

    AMPK Metabolic Disease
    AMPK activator 4 is a potent AMPK activator without inhibition of mitochondrial complex I. AMPK activator 4 selectively activates AMPK in the muscle tissues. AMPK activator 4 dose-dependently improves glucose tolerance in normal mice, and significantly lowers fasting blood glucose level and ameliorates insulin resistance in db/db diabetic mice. Anti-hyperglycemic effect .
    AMPK activator 4
  • HY-101064S2

    N-FMOC-leucine-d3; NPC 15199-d3; NSC 334290-d3

    PPAR
    Fmoc-leucine-d3 is the deuterium labeled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity[1].
    Fmoc-leucine-d3
  • HY-101064S3

    PPAR
    Fmoc-leucine-d10 is the deuterium labeled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity[1].
    Fmoc-leucine-d10
  • HY-10574
    Rilpivirine
    5+ Cited Publications

    R278474; TMC278; db08864

    HIV Reverse Transcriptase Infection
    Rilpivirine (R278474) is a potent and specific diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitor (NNRTI). Rilpivirine has high antiviral activity against wild-type HIV (EC50=0.4 nM) and mutant viruses (EC50=0.1-2.0 nM). Rilpivirine has a high genetic barrier to resistance development of HIV .
    Rilpivirine
  • HY-120657

    Endogenous Metabolite
    9-PAHSA is an orally available anti-inflammatory lipid that lowers blood sugar and reduces inflammation. 9-PAHSA also improved carotid vascular calcification and attenuates cardiac hypertrophy and dysfunction in db/db mice. 9-PAHSA increases the viability of steatosis primary mouse hepatocytes (PMH). 9-PAHSA can be used in research on diabetes, inflammation, and cardiovascular disease .
    9-PAHSA
  • HY-112234

    Sepiapterin

    Endogenous Metabolite Cancer
    L-Sepiapterin (Sepiapterin) is a precursor of the endothelial nitric oxide synthase (eNOS) cofactor tetrahydrobiopterin (BH4). L-Sepiapterin improves endothelial dysfunction in small mesenteric arteries from db/db mice, and induces angiogenesis. L-Sepiapterin inhibits cell proliferation and migration of ovarian cancer cells via down-regulation of p70 S6K-dependent VEGFR-2 expression .
    L-Sepiapterin
  • HY-P1843

    Arenavirus Infection
    Glycoprotein (276-286) is a Db-restricted peptide derived from lymphocytic choriomeningitis virus (LCMV) glycoprotein (GP), corresponds to amino acids 276-286[1].
    Glycoprotein (276-286)
  • HY-18555
    TMPA
    1 Publications Verification

    Nuclear Hormone Receptor 4A/NR4A AMPK Metabolic Disease Inflammation/Immunology Cancer
    TMPA is a high-affinity Nur77 antagonist that binds to Nur77 leading to the release and shuttling of LKB1 in the cytoplasm to activate AMPKα. TMPA effectively lowers blood glucose and attenuates insulin resistance in type II db/db, high-fat diet and streptozotocin-induced diabetic mice. TMPA reduces RICD (restimulation-induced cell death) in human T cells, can also be used in studies of cancer and T-cell apoptosis dysregulation .
    TMPA
  • HY-P1788

    Influenza Virus Infection
    Influenza A NP(366-374) Strain A/PR/8/35 is an H2-Db-restricted epitope from Influenza A/PR/8/35 nucleoprotein .
    Influenza A NP(366-374) Strain A/PR/8/35
  • HY-B1751C

    Parasite Cytochrome P450 Potassium Channel Infection
    Quinidine hydrobromide is an antiarrhythmic agent. Quinidine is a potent, orally active, selective cytochrome P450db inhibitor. Quinidine hydrobromide is also a K + channel blocker with an IC50 of 19.9 μM. Quinidine hydrobromide can be used for malaria research .
    Quinine hydrobromide
  • HY-149924

    PROTACs IAP Cancer
    CST626 (Compound 9) is a pan-IAP degrader PROTAC. PROTAC pan-IAP degrader-1 degrades XIAP, cIAP1 and cIAP2 with DC50s of 0.7, 2.4, and 6.2 nM in MM.1S cells, respectively .
    CST626
  • HY-B1751B

    Quinidine sulfate is an antiarrhythmic agent. Quinidine sulfate is a potent, orally active, selective cytochrome P450db inhibitor. Quinidine sulfate is also a K + channel blocker with an IC50 of 19.9 μM. Quinidine sulfate can be used for malaria research .
    Quinine sulfate
  • HY-B1751F

    Parasite Potassium Channel Cytochrome P450 Apoptosis Infection Cardiovascular Disease Cancer
    Quinate is an antiarrhythmic agent. Quinate is a potent, orally active, selective cytochrome P450db inhibitor. Quinate is also a K + channel blocker with an IC50 of 19.9 μM, and can induce apoptosis. Quinate can be used for malaria research .
    Quinidine gluconic acid
  • HY-P0323

    Arenavirus Infection
    GP(33-41), a 9-aa-long peptide, is the optimal sequence of the GP1 epitope of lymphocytic choriomeningitis virus, and can upregulate H-2D b molecules at the RMA-S (Db Kb) cell surface with a SC50 of 344 nM .
    GP(33-41)
  • HY-B1751
    Quinidine (15% dihydroquinidine)
    Maximum Cited Publications
    14 Publications Verification

    Potassium Channel Cytochrome P450 Apoptosis Parasite Infection Cardiovascular Disease Cancer
    Quinidine (15% dihydroquinidine) is an antiarrhythmic agent. Quinidine is a potent, orally active, selective cytochrome P450db inhibitor. Quinidine is also a K + channel blocker with an IC50 of 19.9 μM, and can induce apoptosis. Quinidine can be used for malaria research .
    Quinidine (15% dihydroquinidine)
  • HY-B1751A

    Parasite Potassium Channel Cytochrome P450 Apoptosis Infection Cardiovascular Disease Cancer
    Quinidine Monosulfate is an antiarrhythmic agent. Quinidine Monosulfate is a potent, orally active, selective cytochrome P450db inhibitor. Quinidine Monosulfate is also a K + channel blocker with an IC50 of 19.9 μM, and can induce apoptosis. Quinidine Monosulfate can be used for malaria research .
    Quinidine sulfate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: